VERTEX PHARMACEUTICALS, INC.
BOSTON, MA

Vertex Pharmaceuticals Incorporated is a globally recognized biopharmaceutical company, headquartered in Boston, Massachusetts. Established on July 27, 2010, Vertex specializes in the discovery, development, and commercialization of innovative medicines for serious diseases. The company's flagship products include KALYDECO and ORKAMBI, both recognized by their distinctive logos as registered trademarks, along with SYMDEKO, also trademarked under Vertex Pharmaceuticals Incorporated. Vertex is renowned for its commitment to advancing treatments that target unmet medical needs, particularly in the realm of rare diseases such as cystic fibrosis. The company employs a strategic approach to identify genetic drivers of serious illnesses and develops transformative medicines that improve patients' everyday lives. As per the official records, Vertex Pharmaceuticals Incorporated is listed under Active with a filing number F10000003409. Its mailing address is 50 Northern Avenue, Boston, MA, 02210, US. For contact purposes, the company provides several phone numbers, accessible at (617) 341-6100; (617) 341-6992; (617) 961-0585; and toll-free at (877) 752-5933. The leadership team includes Alan Garber and Bruce Sachs as Directors, with Charles Wagner Jr. serving in a prominent role within the company. The corporate governance aims to foster innovation and strategic growth, furthering Vertex's mission of transforming lives through therapeutic excellence. With its last annual report filed on January 26, 2024, for the year 2024, and an FEI number of 043039129, Vertex remains steadfast in its ongoing commitment to scientific advancements and corporate transparency.